JP2015501293A - クラミジア抗原組成物およびその使用 - Google Patents
クラミジア抗原組成物およびその使用 Download PDFInfo
- Publication number
- JP2015501293A JP2015501293A JP2014532199A JP2014532199A JP2015501293A JP 2015501293 A JP2015501293 A JP 2015501293A JP 2014532199 A JP2014532199 A JP 2014532199A JP 2014532199 A JP2014532199 A JP 2014532199A JP 2015501293 A JP2015501293 A JP 2015501293A
- Authority
- JP
- Japan
- Prior art keywords
- chlamydia
- protein
- animal
- amino acid
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000606161 Chlamydia Species 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims description 89
- 108091007433 antigens Proteins 0.000 title description 36
- 102000036639 antigens Human genes 0.000 title description 36
- 239000000427 antigen Substances 0.000 title description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 146
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 116
- 229920001184 polypeptide Polymers 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 56
- 208000007190 Chlamydia Infections Diseases 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- 241001647367 Chlamydia muridarum Species 0.000 claims description 38
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 35
- 241001465754 Metazoa Species 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 230000028993 immune response Effects 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 229940038705 chlamydia trachomatis Drugs 0.000 claims description 23
- 101710178083 Probable outer membrane protein PmpG Proteins 0.000 claims description 21
- 101710178082 Probable outer membrane protein PmpF Proteins 0.000 claims description 20
- 101710178080 Probable outer membrane protein PmpH Proteins 0.000 claims description 19
- 239000002671 adjuvant Substances 0.000 claims description 18
- 206010036790 Productive cough Diseases 0.000 claims description 12
- 210000003802 sputum Anatomy 0.000 claims description 12
- 208000024794 sputum Diseases 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 206010061041 Chlamydial infection Diseases 0.000 claims description 7
- 230000028327 secretion Effects 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 102000000157 3-oxoacyl-(acyl-carrier-protein) reductase Human genes 0.000 claims description 4
- 108010055468 3-oxoacyl-(acyl-carrier-protein) reductase Proteins 0.000 claims description 4
- 102000005367 Carboxypeptidases Human genes 0.000 claims description 4
- 108010006303 Carboxypeptidases Proteins 0.000 claims description 4
- 230000033616 DNA repair Effects 0.000 claims description 4
- 101710088194 Dehydrogenase Proteins 0.000 claims description 4
- 108010046914 Exodeoxyribonuclease V Proteins 0.000 claims description 4
- 108010075285 Nucleoside-Triphosphatase Proteins 0.000 claims description 4
- 102000008021 Nucleoside-Triphosphatase Human genes 0.000 claims description 4
- 230000024932 T cell mediated immunity Effects 0.000 claims description 4
- 201000000902 chlamydia Diseases 0.000 claims description 4
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 102000004291 ribosomal protein L6 Human genes 0.000 claims description 4
- 108090000892 ribosomal protein L6 Proteins 0.000 claims description 4
- 102000007469 Actins Human genes 0.000 claims description 3
- 108010085238 Actins Proteins 0.000 claims description 3
- 108090000860 Endopeptidase Clp Proteins 0.000 claims description 3
- 102100021496 Insulin-degrading enzyme Human genes 0.000 claims description 3
- 108090000828 Insulysin Proteins 0.000 claims description 3
- 101710164702 Major outer membrane protein Proteins 0.000 claims description 3
- 108010006035 Metalloproteases Proteins 0.000 claims description 3
- 102000005741 Metalloproteases Human genes 0.000 claims description 3
- 102000004316 Oxidoreductases Human genes 0.000 claims description 3
- 108090000854 Oxidoreductases Proteins 0.000 claims description 3
- 108010089430 Phosphoproteins Proteins 0.000 claims description 3
- 102000007982 Phosphoproteins Human genes 0.000 claims description 3
- 230000005867 T cell response Effects 0.000 claims description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 3
- 230000001617 migratory effect Effects 0.000 claims description 3
- 102000010562 Peptide Elongation Factor G Human genes 0.000 claims description 2
- 108010077742 Peptide Elongation Factor G Proteins 0.000 claims description 2
- 102000008153 Peptide Elongation Factor Tu Human genes 0.000 claims description 2
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 claims description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 108010063460 elongation factor T Proteins 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 230000002797 proteolythic effect Effects 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000034005 thiol-disulfide exchange Effects 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 101710178085 Probable outer membrane protein PmpE Proteins 0.000 claims 4
- 101710105759 Major outer membrane porin Proteins 0.000 claims 2
- 101100484521 Haloferax volcanii (strain ATCC 29605 / DSM 3757 / JCM 8879 / NBRC 14742 / NCIMB 2012 / VKM B-1768 / DS2) atpF gene Proteins 0.000 claims 1
- 101100110710 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) atpH gene Proteins 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 101150090348 atpC gene Proteins 0.000 claims 1
- 101150099875 atpE gene Proteins 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 97
- 229940024606 amino acid Drugs 0.000 description 89
- 150000001413 amino acids Chemical class 0.000 description 83
- 150000007523 nucleic acids Chemical class 0.000 description 57
- 102000039446 nucleic acids Human genes 0.000 description 49
- 108020004707 nucleic acids Proteins 0.000 description 49
- 150000001875 compounds Chemical class 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 35
- 210000004443 dendritic cell Anatomy 0.000 description 30
- 210000001744 T-lymphocyte Anatomy 0.000 description 27
- 229960005486 vaccine Drugs 0.000 description 25
- -1 PmpE Proteins 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 238000006467 substitution reaction Methods 0.000 description 19
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 18
- 239000012634 fragment Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 230000036039 immunity Effects 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 244000052769 pathogen Species 0.000 description 13
- 102000043131 MHC class II family Human genes 0.000 description 11
- 108091054438 MHC class II family Proteins 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 230000001681 protective effect Effects 0.000 description 9
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 8
- ZLJJDBSDZSZVTF-LXOQPCSCSA-N Trehalose-6,6'-dibehenate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)O1 ZLJJDBSDZSZVTF-LXOQPCSCSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 108010066345 MHC binding peptide Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 4
- 241000498849 Chlamydiales Species 0.000 description 4
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 4
- 206010048461 Genital infection Diseases 0.000 description 4
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 4
- 208000035415 Reinfection Diseases 0.000 description 4
- 108010077895 Sarcosine Proteins 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 229940124447 delivery agent Drugs 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000005000 reproductive tract Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 229940030156 cell vaccine Drugs 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229960002173 citrulline Drugs 0.000 description 3
- 235000013477 citrulline Nutrition 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229940063223 depo-provera Drugs 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010044325 trachoma Diseases 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 2
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 2
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 2
- SXGMVGOVILIERA-UHFFFAOYSA-N 2,3-diaminobutanoic acid Chemical compound CC(N)C(N)C(O)=O SXGMVGOVILIERA-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102000034263 Amino acid transporters Human genes 0.000 description 2
- 108050005273 Amino acid transporters Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108050006947 CXC Chemokine Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 2
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 2
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 2
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 2
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 206010035742 Pneumonitis Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- WTOFYLAWDLQMBZ-LURJTMIESA-N beta(2-thienyl)alanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CS1 WTOFYLAWDLQMBZ-LURJTMIESA-N 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 201000003511 ectopic pregnancy Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 238000002169 hydrotherapy Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940043230 sarcosine Drugs 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJBUEDPLEOHJGE-UHFFFAOYSA-N (2R,3S)-3-Hydroxy-2-pyrolidinecarboxylic acid Natural products OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 1
- YWMBHAIUGXZXHT-WCCKRBBISA-N (2S)-4-amino-2-(ethylamino)-4-oxobutanoic acid 2-(ethylamino)acetic acid Chemical compound CCNCC(O)=O.CCN[C@H](C(O)=O)CC(N)=O YWMBHAIUGXZXHT-WCCKRBBISA-N 0.000 description 1
- YPJJGMCMOHDOFZ-ZETCQYMHSA-N (2s)-2-(1-benzothiophen-3-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CSC2=C1 YPJJGMCMOHDOFZ-ZETCQYMHSA-N 0.000 description 1
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- QFOJOSBBHMKWGY-GRHHLOCNSA-N (2s)-2-amino-3-(2-fluorophenyl)propanoic acid;(2s)-2-amino-3-(3-fluorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(F)=C1.OC(=O)[C@@H](N)CC1=CC=CC=C1F QFOJOSBBHMKWGY-GRHHLOCNSA-N 0.000 description 1
- VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- JHTPBGFVWWSHDL-UHFFFAOYSA-N 1,4-dichloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=S)=C1 JHTPBGFVWWSHDL-UHFFFAOYSA-N 0.000 description 1
- NYCRCTMDYITATC-UHFFFAOYSA-N 2-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1F NYCRCTMDYITATC-UHFFFAOYSA-N 0.000 description 1
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- 101710190981 50S ribosomal protein L6 Proteins 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 101710146995 Acyl carrier protein Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000423293 Chlamydia trachomatis D/UW-3/CX Species 0.000 description 1
- 241001185363 Chlamydiae Species 0.000 description 1
- 241000201562 Chlamydophila pneumoniae AR39 Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004674 D-amino-acid oxidase Human genes 0.000 description 1
- 108010003989 D-amino-acid oxidase Proteins 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 description 1
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- JUQLUIFNNFIIKC-YFKPBYRVSA-N L-2-aminopimelic acid Chemical compound OC(=O)[C@@H](N)CCCCC(O)=O JUQLUIFNNFIIKC-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 101710084374 Major outer membrane protein 1 Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- YOLDOYLSAIXKLP-UHFFFAOYSA-N NC(C(=O)O)CCCCC.NCCCCCC(=O)O Chemical compound NC(C(=O)O)CCCCC.NCCCCCC(=O)O YOLDOYLSAIXKLP-UHFFFAOYSA-N 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101710088839 Replication initiation protein Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 101710148706 Translocated actin-recruiting phosphoprotein Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 101710100790 V-type ATP synthase subunit E Proteins 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- RREGISFBPQOLTM-UHFFFAOYSA-N alumane;trihydrate Chemical compound O.O.O.[AlH3] RREGISFBPQOLTM-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000002821 anti-nucleating effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- VWHRYODZTDMVSS-QMMMGPOBSA-N m-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(F)=C1 VWHRYODZTDMVSS-QMMMGPOBSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000005319 nano flow HPLC Methods 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000002667 nucleating agent Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- YSMODUONRAFBET-WHFBIAKZSA-N threo-5-hydroxy-L-lysine Chemical compound NC[C@@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-WHFBIAKZSA-N 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56927—Chlamydia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
本研究は、少なくとも一部分において、国立アレルギー感染症研究所(NIAID)からの米国連邦政府助成金番号R01AI076483による資金提供を受けた。米国連邦政府は、本発明に関して一定の権利を有し得る。
「クラミジア属(Chlamydia spp.)」は、偏性細胞内寄生体である細菌の属を意味する。クラミジア属(Chlamydia spp.)には、クラミジア・トラコマチス(C. trachomatis)(ヒト病原体)およびクラミジア・ムリダルム(C. muridarum)(マウスおよびハムスターの病原体)が含まれる。クラミジア・ムリダルム(C. muridarum)およびクラミジア・トラコマチス(C. trachomatis)は、それらの宿主種とともに共進化した非常にオルソロガスな病原性微生物であるので、クラミジア・ムリダルム(C. muridarum)は細胞性免疫研究およびワクチン開発のための確固たる動物モデルとして使用されてきた。
本開示による組成物および方法において使用するための化合物には、限定はされないが、本明細書に記載のペプチドまたはポリペプチド、例えば、表1〜4に列挙されるもの、ならびにこれらのペプチドまたはポリペプチドをコードする核酸分子が含まれる。
本明細書に記載の化合物および組成物は、ワクチンまたは他の製剤を調製するのに使用することができる。化合物および組成物は、単独または他の化合物(例えば、核酸分子、小分子、ポリペプチド、ペプチドもしくはペプチド類似体)と組み合わせて、リポソーム、アジュバントまたは任意の医薬的に許容可能な担体の存在下で、動物対象、例えばマウス、ヒト、ブタなどへの投与に適した形態で提供することができる。必要に応じて、本発明による化合物を用いた治療は、クラミジア感染に関するより伝統的なおよび現行の療法と組み合わせることができる。
包装材および本明細書で提供される1つまたは複数のペプチドまたはポリペプチドを含む組成物を含有する製品も提供する。組成物は、生理学的または医薬的に許容可能な適切な賦形剤を含み、アジュバント、送達剤をさらに含むことができ、またはアジュバントおよび送達剤ならびに包装材は、組成物の活性成分(例えば、提示としてペプチドまたはポリペプチド、アジュバントまたは送達剤)を示すラベルを含むことができる。ラベルは、組成物の意図された使用、例えば、本明細書に記載の方法で使用されるべき治療的または予防的組成物としての意図された使用をさらに含むことができる。
別の実施形態では、医薬を調製するためのキットであって、本明細書で提供する1つまたは複数のペプチドを含む組成物を含有するキットが、その使用のための説明書とともに提供される。説明書は、医薬が投与される対象において治療的または予防的な免疫応答を誘導するのに有用な医薬を調製するための一連のステップを含むことができる。キットは、クラミジア感染の1つまたは複数の症状を治療、予防または改善するための治療で医薬を使用するための説明書さらに含むことができ、例えば、服用濃度、服用間隔、好ましい投与方法などを含むことができる。
クラミジア
クラミジア・ムリダルム(C. muridarum)マウス肺炎(MoPn)系統Niggを、10%FCSを補充したイーグル最少必須培地(Invitrogen)中のHela229で増殖させた。基本小体(EB)を、以前に述べられているように(Caldwell, H. D.、J. KromhoutおよびJ. Schachter. 1981. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun 31:1161〜1176.)、不連続密度勾配遠心法によって精製した。精製したEBを分取し、ショ糖−リン酸−グルタミン酸緩衝液中で−80℃で保管し、使用直前に解凍した。精製EBの感染力および封入体形成単位(IFU)数を、抗EBマウスポリクローナル抗体、続いてビオチン標識抗マウスIgG(Jackson ImmunoResearch Laboratories)およびジアミノベンジジン (DAB)基質(Vector Laboratories)を用いる免疫染色(Yang, X.、K. T. HayGlassおよびR. C. Brunham. 1996. Genetically determined differences in IL-10 and IFN-gamma responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection. J Immunol 156:4338〜4344)によって測定した。生きているEBに対するIFUを、上記の元のクラミジア・ムリダルム(C. muridarum)EB精製ストックについて測定した力価から計算した。
雌のC57BL/6またはBALB/cマウス(5から6週齢)をCharles River Canadaから購入し、病原体フリー条件下で飼育した。
本発明で使用するクラミジアワクチン用のT細胞抗原候補を同定するための全プロセスを概略的に図1に示し、より詳細に以下に提供する。
以前の記載(Inaba, K.、M. Inaba, N. Romani、H. Aya、M. Deguchi、S. Ikehara、S. MuramatsuおよびR. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693〜1702)のように、DCを生成した。簡単に述べると、骨髄細胞をBALB/cマウスの大腿骨または脛骨から単離し、Falconのペトリ皿中で、50mlのDC培地中に4×107細胞で培養した。DC培地は、10%FCS、0.5mM 2−ME、4mM L−グルタミン、50μg/mlゲンタマイシン、ならびにそれぞれ10ng/ml GM−CSFおよび10ng/ml IL−4を含んだ、5%のマウスGM−CSFトランスフェクト形質細胞腫X63−Ag8の培養上清および5%のマウスIL−4トランスフェクト形質細胞腫X63−Ag8の培養上清を補充した、イスコフ改変ダルベッコ培地(IMDM)である。3日目に培養上清の半分を除去し、新鮮なDC培地を加えた。5日目に、骨髄由来樹状細胞(BM−DC)と呼ばれる非付着細胞(>50%CD11c+の純度)を新しいシャーレに移し、25×107IFUの生きているEBを含む50mlのDC培地中に25×107細胞で、37℃、5%CO2で12時間培養した。次いで、生きているEBでパルスされた細胞を回収し、−80℃で保管した。
本発明者らは、生きているEBでパルスされた6×109のBM−DCを獲得した。パルスされたDCからMHCクラスII結合ペプチドを同定するための、多数のステップが含まれる免疫プロテオーム法が以前に述べられている(Karunakaran, K. P.、J. Rey-Ladino、N. Stoynov、K. Berg、C. Shen、X. Jiang、B. R. Gabel、H. Yu、L. J. FosterおよびR. C. Brunham. 2008. Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia. J Immunol 180:2459〜2465)。簡単に述べると、パルスされたDCを溶解し、対立遺伝子特異的抗MHCモノクローナル抗体アフィニティーカラムを用いて、MHCクラスII(I−Ab)分子を精製した。次いで、アフィニティーカラムに結合したMHCクラスII分子を溶出し、酢酸処理および高分子量物質を除去するための5−kDaカットオフ膜による限外濾過によって、MHC結合ペプチドをMHC分子から分離した。ナノスプレーイオン化源を用いるナノフローHPLCにオンラインで連結されたLTQ−OrbitrapXL(Thermo Electron)を使用して、精製MHC結合ペプチドを定性的に分析した。この質量分析計は、サイクルあたり最も強い5つの多荷電イオンをフラグメント化するようにセットする。フラグメントスペクトルをDTASuperCharge(http://msquant.sourceforge.net)を用いて抽出し、クラミジア・ムリダルム(C. muridarum)由来のタンパク質配列からなるデータベースに対して、Mascotアルゴリズムを用いて検索する。
GraphPad Prismソフトウェアプログラムを用いてデータを分析した。クラスカル・ウォリスの検定を実施して、多数の群からのクラミジア・ムリダルム(C. muridarum)の排出についてデータを分析し、マンホイットニーのU検定を用いて、ペア間の中央値を比較した。<0.05のP値を有意とみなした。データは、平均値±平均値の標準誤差(SEM)として示す。
表1に、若干修正した実験条件下で免疫プロテオーム法を適用することによって同定された抗原を列挙する。この場合、骨髄由来樹状細胞(BM−DC)を、(C57BL/6系統と対立するものとして)BALB/cマウスから単離し、クラミジア・ムリダルム(C. muridarum)とともに12時間インキュベートした。
クラミジア感染のマウス生殖器モデルにおいて、免疫プロテオーム法によって同定し、選択したT細胞抗原を、防御的なワクチン効率について評価した。これらのタンパク質(PmpG、PmpF、PmpE、PmpH、RplF、Aasf、RecO、Tarp、AtpE、TC0420、TC0190、TC0825およびTC0285)は、ヒトタンパク質とほとんどまたは全く配列相同性を有さず、クラミジアまたはクラミジア近縁種に存在する。引き続く免疫化研究用に、これらのタンパク質をクローニングし、発現し、精製した。
Claims (22)
- SPQVLTPNVIIPFKGDD、SMLIIPALGG、LAAAVMHADSGAILKEK、DDPEVIRAYIVPPKEP、KIFSPAGLLSAFAKNGA、DPVDMFQMTKIVSKH、KLEGIINNNNTPS、AVPRTSLIF、GGAEVILSRSHPEFVKQ、APILARLSと実質的に同一のアミノ酸配列を含むポリペプチドまたはそれらの組み合わせを生理学的に許容可能な担体とともに含む、免疫原性組成物。
- ポリペプチドが、多型膜タンパク質H(PmpH)、ヌクレオシドトリホスファターゼ(YggV)、D−アナリル(analyl)−D−アラニンカルボキシペプチダーゼ(DacC)、ローカスタグCT538に対応する推定タンパク質、DNA修復タンパク質(RecO)、SWIB(YM74)複合体タンパク質、移行性アクチン動員リンタンパク質(Tarp)、エキソデオキシリボヌクレアーゼVのαサブユニット(RecD_2)、N利用サブスタンスタンパク質A(NusA)、ローカスタグCT017に対応する推定タンパク質と実質的に同一のアミノ酸配列またはそれらの組み合わせを含み、生理学的に許容可能な担体を伴う、請求項1に記載の組成物。
- AFHLFASPAANYIHTG、NAKTVFLSNVASPIYVDPA、ASPIYVDPAAAGGQPPA、VKGNEVFVSPAAHIIDRPG、SPGQTNYAAAKAGIIGFS、KLDGVSSPAVQESISE、IGQEITEPLANTVIA、MTTVHAATATQSVVD、DLNVTGPKIQTDVD、EGTKIPIGTPIAVFSTEQN、SVPSYVYYPSGNRAPVV、YDHIIVTPGANADIL、LPLMIVSSPKASESGAA、GANAIPVHCPIGAESQ、VFWLGSKINIIDTPG、ISRALYTPVNSNQSVG、FEVQLISPVALEEGMR、GDAAYIEKVRELMQ、SRALYAQPMLAISEA、またはKPAEEEAGSIVHNAREQと実質的に同一のアミノ酸配列を含むポリペプチドまたはそれらの組み合わせをさらに含む、請求項1または2に記載の組成物。
- 多型膜タンパク質F(PmpF)、多型膜タンパク質G(PmpG)、リボソームタンパク質L6(RplF)、3−オキソアシル−(アシルキャリアータンパク質)還元酵素(FabG)、抗抗シグマ因子(Aasf)、ATP依存性Clpプロテアーゼのタンパク分解性サブユニット(ClpP)、グリセルアルデヒド3リン酸脱水素酵素(Gap)、ローカスタグCT143に対応する推定タンパク質、ピルビン酸脱水素酵素(PdhC)、チオールジスルフィド交換タンパク質(DsbD)、酸化還元酵素のDadAファミリー、メタロプロテアーゼのインスリナーゼファミリー、翻訳伸長因子G(FusA)、翻訳伸長因子Ts(Tsf)、翻訳伸長因子Tu(Tuf)、多型膜タンパク質E(PmpE)、V型ATP合成酵素サブユニットE(AtpE)と実質的に同一のアミノ酸配列を含むポリペプチドまたはそれらの組み合わせをさらに含む、請求項1または2に記載の組成物。
- PmpG、PmpE、PmpFおよびPmpHならびに場合によりMOMPを含む、請求項1から4のいずれか一項に記載の組成物。
- PmpG、PmpE、PmpFおよびTC0420ならびに場合によりMOMPを含む、請求項1から4のいずれか一項に記載の組成物。
- アジュバントをさらに含む、請求項1から6のいずれか一項に記載の組成物。
- アジュバントがDDA/TDB、DDA/MMGまたはDDA/MPLから選択される、請求項7に記載の組成物。
- 動物において、クラミジア属(Chlamydia spp.)またはそれらの成分に対して免疫応答を惹起するための方法であって、有効量の請求項1から8のいずれか一項に記載の組成物を動物に投与し、それによって動物において免疫応答を惹起することを含む、方法。
- 免疫応答が細胞性免疫応答である、請求項9に記載の方法。
- 動物においてクラミジア属(Chlamydia spp.)による感染を治療または予防するための方法であって、有効量の請求項1から8のいずれか一項に記載の組成物を動物に投与し、それによって動物においてクラミジア属(Chlamydia spp.)による感染を治療または予防することを含む方法。
- クラミジア属(Chlamydia spp.)がクラミジア・トラコマチス(Chlamydia trachomatis)またはクラミジア・ムリダルム(Chlamydia muridarum)である、請求項9から11のいずれか一項に記載の方法。
- 動物がヒトである、請求項9から12のいずれか一項に記載の方法。
- 動物においてクラミジア属(Chlamydia spp.)またはそれらの成分に対して免疫応答を惹起するための、請求項1から9のいずれか一項に記載の組成物の使用。
- 免疫応答が細胞性免疫応答である、請求項13に記載の使用。
- 動物において、クラミジア属(Chlamydia spp.)による感染を治療または予防するための、請求項1から9のいずれか一項に記載の組成物の使用。
- クラミジア属(Chlamydia spp.)がクラミジア・トラコマチス(Chlamydia trachomatis)またはクラミジア・ムリダルム(Chlamydia muridarum)である、請求項14〜16のいずれか一項に記載の使用。
- 動物がヒトである、請求項14〜16のいずれか一項に記載の使用。
- 動物において、クラミジア感染を診断する方法であって、SPQVLTPNVIIPFKGDD、SMLIIPALGG、LAAAVMHADSGAILKEK、DDPEVIRAYIVPPKEP、KIFSPAGLLSAFAKNGA、DPVDMFQMTKIVSKH、KLEGIINNNNTPS、AVPRTSLIF、GGAEVILSRSHPEFVKQ、またはAPILARLSと実質的に同一のアミノ酸配列を含むポリペプチドに対するT細胞応答が動物由来のサンプル中に存在するかしないかを判定すること、ここでT細胞応答の存在は動物のクラミジア感染を示す、を含む、方法。
- ポリペプチドが、多型膜タンパク質H(PmpH)、ヌクレオシドトリホスファターゼ(YggV)、D−アナリル(analyl)−D−アラニンカルボキシペプチダーゼ(DacC)、ローカスタグCT538に対応する推定タンパク質、DNA修復タンパク質(RecO)、SWIB(YM74)複合体タンパク質、移行性アクチン動員リンタンパク質(Tarp)、エキソデオキシリボヌクレアーゼVのαサブユニット(RecD_2)、N利用サブスタンスタンパク質A(NusA)、ローカスタグCT017に対応する推定タンパク質と実質的に同一のアミノ酸配列を含む、請求項21に記載の方法。
- サンプルが、腟液、腟組織、腟洗浄液、腟スワブ、尿道スワブ、尿、血液、血清、血漿、唾液、精液、尿道分泌物、腟分泌物、眼液、眼分泌物またはそれらの任意の組み合わせからなる、請求項20または21に記載の方法。
- 動物がヒトである、請求項20〜21のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161541944P | 2011-09-30 | 2011-09-30 | |
US61/541,944 | 2011-09-30 | ||
PCT/CA2012/050691 WO2013044398A1 (en) | 2011-09-30 | 2012-10-01 | Chlamydia antigen compositions and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015501293A true JP2015501293A (ja) | 2015-01-15 |
JP2015501293A5 JP2015501293A5 (ja) | 2015-11-19 |
Family
ID=47994085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014532199A Pending JP2015501293A (ja) | 2011-09-30 | 2012-10-01 | クラミジア抗原組成物およびその使用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20150010591A1 (ja) |
EP (1) | EP2760468A4 (ja) |
JP (1) | JP2015501293A (ja) |
KR (1) | KR20140088108A (ja) |
CN (1) | CN103987404A (ja) |
AU (1) | AU2012315429A1 (ja) |
CA (1) | CA2850228A1 (ja) |
HK (1) | HK1200724A1 (ja) |
WO (1) | WO2013044398A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016530203A (ja) * | 2013-08-29 | 2016-09-29 | ビーエーエスエフ コンストラクション ソリューションズ ゲゼルシャフト ミット ベシュレンクテル ハフツングBASF Construction Solutions GmbH | エトリンガイトおよびケイ酸カルシウム水和物を含有する硬化促進剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104812406A (zh) * | 2012-08-08 | 2015-07-29 | 英属哥伦比亚大学 | 衣原体抗原组合物及其用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002517179A (ja) * | 1997-11-28 | 2002-06-18 | ジェンセット | Chlamydiatrachomatisゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用 |
JP2008520550A (ja) * | 2004-10-25 | 2008-06-19 | ステーテンズ セーラム インスティテュート | クラミジア・トラコマチス(Chlamydiatrachomatis)抗原のワクチンおよび診断への使用 |
WO2008156729A2 (en) * | 2007-06-14 | 2008-12-24 | Emergent Product Development Gaithersburg Inc. | Vaccines against chlamydia infection |
WO2010085896A1 (en) * | 2009-01-29 | 2010-08-05 | British Columbia Cancer Agency Branch | Compositions comprising chlamydia antigens |
JP2010530229A (ja) * | 2007-06-18 | 2010-09-09 | インターセル アーゲー | クラミジア属の抗原 |
WO2010100632A2 (en) * | 2009-03-06 | 2010-09-10 | Novartis Ag | Chlamydia antigens |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041490B1 (en) * | 1997-11-28 | 2006-05-09 | Serono Genetics Institute, S.A. | Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same |
US6448234B1 (en) * | 1998-12-08 | 2002-09-10 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
DE60133190T2 (de) * | 2000-04-21 | 2009-04-02 | CORIXA CORP., Wilmington | Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen |
EP2392348A3 (en) * | 2005-03-31 | 2012-01-18 | GlaxoSmithKline Biologicals S.A. | Vaccines against chlamydial infection |
CA2633142A1 (en) * | 2005-12-22 | 2007-10-04 | Novartis Vaccines And Diagnostics, S.R.L. | Chlamydial antigens |
CN104812406A (zh) * | 2012-08-08 | 2015-07-29 | 英属哥伦比亚大学 | 衣原体抗原组合物及其用途 |
-
2012
- 2012-10-01 AU AU2012315429A patent/AU2012315429A1/en not_active Abandoned
- 2012-10-01 WO PCT/CA2012/050691 patent/WO2013044398A1/en active Application Filing
- 2012-10-01 US US14/348,160 patent/US20150010591A1/en not_active Abandoned
- 2012-10-01 CN CN201280058664.2A patent/CN103987404A/zh active Pending
- 2012-10-01 CA CA2850228A patent/CA2850228A1/en not_active Abandoned
- 2012-10-01 JP JP2014532199A patent/JP2015501293A/ja active Pending
- 2012-10-01 KR KR1020147010996A patent/KR20140088108A/ko not_active Application Discontinuation
- 2012-10-01 EP EP12836110.2A patent/EP2760468A4/en not_active Withdrawn
-
2015
- 2015-02-05 HK HK15101278.4A patent/HK1200724A1/xx unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002517179A (ja) * | 1997-11-28 | 2002-06-18 | ジェンセット | Chlamydiatrachomatisゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用 |
JP2008520550A (ja) * | 2004-10-25 | 2008-06-19 | ステーテンズ セーラム インスティテュート | クラミジア・トラコマチス(Chlamydiatrachomatis)抗原のワクチンおよび診断への使用 |
WO2008156729A2 (en) * | 2007-06-14 | 2008-12-24 | Emergent Product Development Gaithersburg Inc. | Vaccines against chlamydia infection |
JP2010530229A (ja) * | 2007-06-18 | 2010-09-09 | インターセル アーゲー | クラミジア属の抗原 |
WO2010085896A1 (en) * | 2009-01-29 | 2010-08-05 | British Columbia Cancer Agency Branch | Compositions comprising chlamydia antigens |
WO2010100632A2 (en) * | 2009-03-06 | 2010-09-10 | Novartis Ag | Chlamydia antigens |
Non-Patent Citations (1)
Title |
---|
YU,H. ET AL.: "Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against inf", INFECT. IMMUN., vol. 78, no. 5, JPN6016021526, May 2010 (2010-05-01), pages 2272 - 2282, XP055148827, ISSN: 0003335000, DOI: 10.1128/IAI.01374-09 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016530203A (ja) * | 2013-08-29 | 2016-09-29 | ビーエーエスエフ コンストラクション ソリューションズ ゲゼルシャフト ミット ベシュレンクテル ハフツングBASF Construction Solutions GmbH | エトリンガイトおよびケイ酸カルシウム水和物を含有する硬化促進剤 |
Also Published As
Publication number | Publication date |
---|---|
EP2760468A1 (en) | 2014-08-06 |
WO2013044398A1 (en) | 2013-04-04 |
US20150010591A1 (en) | 2015-01-08 |
AU2012315429A1 (en) | 2014-05-01 |
KR20140088108A (ko) | 2014-07-09 |
HK1200724A1 (en) | 2015-08-14 |
CN103987404A (zh) | 2014-08-13 |
CA2850228A1 (en) | 2013-04-04 |
EP2760468A4 (en) | 2015-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7892567B2 (en) | Methods and compositions for immunization against chlamydial infection and disease | |
KR102126398B1 (ko) | 돼지 생식기 호흡기 증후군 (prrs)의 효과적인 제어를 위한 합성 펩티드-기반 마커 백신 및 진단 시스템 | |
JP2001518489A (ja) | クラミジアタンパク質、その遺伝子配列および使用 | |
JP2008022856A (ja) | 肺炎連鎖球菌由来の核酸及びタンパク質 | |
JP2001518489A5 (ja) | ||
BR112015014727B1 (pt) | Composição imunogênica, uso de uma composição imunogênica, e, método para prevenir ou tratar a doença c.difficile | |
CA2739111A1 (en) | Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease | |
CA2683888A1 (en) | Chlamydial antigens as reagents for diagnosis and treatment of chlamydial infection and disease | |
JP2015501293A (ja) | クラミジア抗原組成物およびその使用 | |
WO2014022936A1 (en) | Chlamydia antigen compositions and uses thereof | |
EP2907523B1 (en) | Compositions comprising chlamydia antigens | |
US20240066111A1 (en) | Lawsonia intracellularis compositions and methods of using the same | |
WO2010089340A2 (en) | Peptides protective against e. faecalis, methods and uses relating thereto | |
US20160045588A1 (en) | Chlamydia antigen compositions and uses thereof | |
JP2003530358A (ja) | クラミジア糖脂質ワクチン | |
AU2016349937B2 (en) | Chlamydia antigens and uses thereof | |
WO2023006825A1 (en) | Novel pneumococcal polypeptide antigens | |
EP1943269A2 (en) | Neisseria meningitidis antigens | |
US20060257429A1 (en) | Vaccine for periodontal disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150930 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150930 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160614 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160909 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161214 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170321 |